Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.DSM Pharmaceutical Products has signed a 3-year master supply agreement with Eisai for the production of sterile products.
Subscribe to our email newsletter
The agreement aims to manufacture eribulin mesylate as well as other developmental drugs.
DSM Pharmaceutical Products president and CEO Alexander Wessels said, "We are delighted to be working with Eisai under a long-term agreement to serve markets globally for important human health treatments, bringing our expertise and reliability in sterile injectables and worldwide regulatory record to ensure market supply."
DSM will be a supplier for eribulin mesylate to the US market. Commercial production is anticipated to start in early 2013.